Strategic partnerships TechnoVax is actively pursuing strategic partnerships and has a track record of collaborating with biotech entities to advance vaccine development and manufacturing, presenting a readily explorable avenue for co-development, licensing, and manufacturing agreements.

VLP platform leverage With a focus on virus-like particle vaccines targeting respiratory diseases, hemorrhagic fevers, immunodeficiency, and cancers, there is a clear opportunity to position TechnoVax as a platform provider for partners seeking versatile, scalable VLP-based vaccine solutions.

Non-dilutive funding The company has secured over five million dollars in non-dilutive funding, signaling fiscal prudence and potential for grant-backed collaborations, which can de-risk early-stage partnerships and accelerate joint development timelines.

Near-clinical pipeline Three lead candidates including a universal flu vaccine, an inhaled powder flu vaccine, and an RSV vaccine indicate multiple high-impact, market-ready targets with potential for upfront collaboration across development, trials, and regulatory pathways.

Small company agility With a lean team and a private, near-clinical posture based in Tarrytown, NY, TechnoVax offers flexibility for fast decision-making, tailored partnership structures, and potential for co-funded pilot programs with larger industry players.